Stockreport

Zomedica Completes Verification of its TRUFORMA™ Point-of-Care Diagnostic Platform and the First Assay, Canine total T4

Zomedica Corp. Common Shares  (ZOM) 
US:NYSE Investor Relations: investors.zomedica.com
PDF ANN ARBOR, Mich., April 21, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company [Read more]